State Street Corp Aravive, Inc. Transaction History

State Street Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.11 - $1.76 $2,332 - $37,312	21,200 Added 36.56%	79,187 $10,000
Q1 2023 May 15, 2023	BUY	$1.29 - $2.46 $33,540 - $63,960	26,000 Added 81.28%	57,987 $115,000
Q2 2021 Aug 16, 2021	SELL	$4.65 - $6.42 $810,783 - $1.12 Million	-174,362 Reduced 84.5%	31,987 $191,000
Q1 2021 May 17, 2021	BUY	$5.11 - $9.24 $94,024 - $170,016	18,400 Added 9.79%	206,349 $1.36 Million
Q4 2020 Feb 16, 2021	SELL	$4.36 - $6.51 $10,900 - $16,275	-2,500 Reduced 1.31%	187,949 $1.06 Million
Q3 2020 Nov 10, 2020	BUY	$4.7 - $12.06 $95,917 - $246,120	20,408 Added 12.0%	190,449 $895,000
Q2 2020 Aug 14, 2020	BUY	$5.18 - $14.81 $880,812 - $2.52 Million	170,041 New	170,041 $1.98 Million

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.